May 28, 2025 - Lenexa, KS, USA
Eurofins Viracor announced today the launch of its new quantitative real-time PCR assays for dimorphic fungi, a significant advancement in the rapid and accurate diagnosis of infections caused by Blastomyces spp., Histoplasma spp., Coccidioides spp., and Cryptococcus (C. gattii and/or C. neoformans). These advanced molecular tests are designed to empower clinicians with timely and reliable diagnostic information, facilitating prompt and targeted treatment for potentially life-threatening fungal infections.
Dimorphic fungal infections pose a considerable challenge in clinical settings, often leading to severe illness and increased patient morbidity and mortality due to factors such as diagnostic delays. Traditional diagnostic methods such as culture, serology, and microscopy can be slow, insensitive, or lack specificity, hindering timely therapeutic intervention, especially in immunocompromised patients or those with acute presentations like meningitis or severe pulmonary disease.
Key benefits of these new assays include:
These new assays address a significant unmet need in the clinical microbiology market by leveraging the power of molecular diagnostics to provide fast, highly sensitive, and specific detection of critical fungal pathogens. Eurofins Viracor's commitment to innovation in infectious disease diagnostics is exemplified by this advancement.
For more information about the dimorphic fungal assays and their applications, please visit
Our Testing | Fighting Fungals or contact Client Services at (800) 305-5198.
Notes to Editors:
For more information, please contact:
Rob Horel, Vice President Commercial
Eurofins Viracor
Rob.Horel@Viracor.EurofinsUS.com
About Eurofins Viracor
With over 40 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Eurofins Viracor is committed to helping medical professionals, transplant teams and reference laboratories get results faster, when it matters most. Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves.
Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit eurofins-viracor.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing and in-vitro diagnostic products.
With ca. 63,000 staff across a decentralized and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.
The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions.
Shares in Eurofins Scientific SE are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).